Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Clinical trial NCT02039947 · COMPLETED
Trial details
- NCT number
- NCT02039947
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-21
- Primary completion
- 2017-05-12
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.